glp-1 news today october 20 2025 weight loss drugs leave users low on key nutrients, study finds 🚨 Top-Line Results: Mazdutide vs.

And the differences go far beyond the number on the scale

Key Features with Phoenix NP 01

The distinction lies in their FDA-approved uses: Mounjaro is approved for treating type 2 diabetes, while Zepbound is approved for chronic weight management

Nestle is already having to educate people that it sells a lot of water, coffee, baby food (Gerber FTW) and not as many KitKats as people think

In another systematic review that included individuals with T2D from 38 phase III or IV placebo-controlled randomized controlled trials with GLP-1RAbased therapy (16), nausea was reported in 19.3% of participants with active treatment versus 6.5% with placebo, and vomiting was reported in 7.6% of participants versus 2% with placebo